Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 72 results for menopause

  1. Obesity prevention (CG43)

    This guideline covers preventing children, young people and adults becoming overweight or obese. It outlines how the NHS, local authorities, early years’ settings, schools and workplaces can increase physical activity levels and make dietary improvements among their target populations.

  2. Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment (IPG772)

    Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.

  3. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  4. Transvaginal laser therapy for urogenital atrophy (IPG697)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  5. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  6. Endometriosis (QS172)

    This quality standard covers diagnosing and managing endometriosis in women, including young women aged 17 and under. It describes high-quality care in priority areas for improvement.

  7. Effects of HRT on dementia risk:- What are the effects of early HRT use on the risk of dementia?

    natural menopause, including women with premature ovarian insufficiency. Source guidance details Comes from guidance...

  8. Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions?

    Women with premature ovarian insufficiency can experience the effects of menopause for most of their adult life. This can lead to...

  9. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    The choice of surgery will also be affected by whether you have had your menopause or not, any previous surgery you may have had, and...

  10. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  11. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

  12. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis. It aims to raise awareness of the symptoms of endometriosis, and to provide clear advice on what action to take when women and people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  13. Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

    symptoms. Source guidance details Comes from guidance Menopause: diagnosis and management Number NG23 Date issued

  14. Ovarian cancer (QS18)

    This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.